European Society of Hypertension position paper on renal denervation 2021
Top Cited Papers
- 13 July 2021
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Hypertension
- Vol. 39 (9), 1733-1741
- https://doi.org/10.1097/hjh.0000000000002933
Abstract
This ESH Position Paper 2021 with updated proposed recommendations was deemed necessary after the publication of a set of new pivotal sham-controlled randomized clinical trials (RCTs), which provided important information about the efficacy and safety of endovascular device-based renal denervation (RDN) for hypertension treatment. RDN is effective in reducing or interrupting the sympathetic signals to the kidneys and decreasing whole body sympathetic activity. Five independent, fully completed, sham-controlled RCTs provide conclusive evidence that RDN lowers ambulatory and office blood pressure (BP) to a significantly greater extent than sham treatment. BP-lowering efficacy is evident both in patients with and without concomitant antihypertensive medication. The average decrease of 10 mmHg in office BP is estimated to lower the incidence of cardiovascular events by 25–30%, based on meta-analyses of RCTs using pharmacological treatment. Neither peri-procedural, nor short-term or long-term adverse events or safety signals (available up to 3 years) have been observed. Implementing RDN as an innovative third option in the armamentarium of antihypertensive treatment requires a structured process that ensures the appropriate performance of the endovascular RDN procedure and adequate selection of hypertensive patients. The latter should also incorporate patients’ perspective and preference that needs to be respected in a shared decision-making process.Keywords
This publication has 41 references indexed in Scilit:
- Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysisThe Lancet, 2015
- Mid-Term Vascular Safety of Renal Denervation Assessed by Follow-up MR ImagingCardioVascular and Interventional Radiology, 2015
- Blood Pressure Responses to Renal Denervation Precede and Are Independent of the Sympathetic and Baroreflex EffectsNovelty and SignificanceHypertension, 2015
- Wilder's principle: pre-treatment value determines post-treatment responseEuropean Heart Journal, 2014
- Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trialsJournal of Hypertension, 2014
- Predictors of blood pressure response in the SYMPLICITY HTN-3 trialEuropean Heart Journal, 2014
- A Controlled Trial of Renal Denervation for Resistant HypertensionThe New England Journal of Medicine, 2014
- Vascular lesions induced by renal nerve ablation as assessed by optical coherence tomography: pre- and post-procedural comparison with the Simplicity® catheter system and the EnligHTN™ multi-electrode renal denervation catheterEuropean Heart Journal, 2013
- Substantial Reduction in Single Sympathetic Nerve Firing After Renal Denervation in Patients With Resistant HypertensionHypertension, 2013
- Cost-Effectiveness and Clinical Effectiveness of Catheter-Based Renal Denervation for Resistant HypertensionJournal of the American College of Cardiology, 2012